As newer noninvasive screening tools flood the market, the fecal immunochemical test (FIT) continues to hold its ground—quietly, effectively, and with patient-friendly convenience. In this Medscape commentary, Dr. Kenny Lin revisits the data behind FIT, including results from a major European trial showing no significant difference in colorectal cancer deaths between FIT and colonoscopy over a 10-year span.
But FIT’s continued relevance depends on one critical factor: patient follow-through. Can small changes—like using liquid vials, tweaking instructions, or adding a deadline—make a big difference in adherence? Evidence says yes.